ArticleGastroenterology research and practice2010
NF-κB, JNK, and TLR Signaling Pathways in Hepatocarcinogenesis.
Article in Gastroenterology research and practice, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 59 citations in OpenAlex.
- Article
- Next-Generation Sequencing Identifies Novel Germline Mutations in Patients with Budd-Chiari Syndrome-Associated Hepatocellular Carcinoma.Digestive diseases and sciences · 2025Article
- Overfeeding in the early postnatal period aggravates inflammation and hepatic insulin sensitivity in the 5α-dihydrotestosterone-induced animal model of PCOS.Frontiers in endocrinology · 2024Article
- Tollip promotes hepatocellular carcinoma progression via PI3K/AKT pathway.Open medicine (Warsaw, Poland) · 2022Article
- Anti-inflammatory activity of psoralen in human periodontal ligament cells via estrogen receptor signaling pathway.Scientific reports · 2021Article
- Immunity as Cornerstone of Non-Alcoholic Fatty Liver Disease: The Contribution of Oxidative Stress in the Disease Progression.International journal of molecular sciences · 2021Review
- Review
- Mesenchymal stromal cells induce inhibitory effects on hepatocellular carcinoma through various signaling pathways.Cancer cell international · 2019Review
- Anti-hepatitis B virus (HBV) response of imiquimod based toll like receptor 7 ligand in hbv-positive human hepatocelluar carcinoma cell line.BMC infectious diseases · 2017Article
- Toll-like receptors in pathophysiology of liver diseases.World journal of hepatology · 2016Review
- Extracellular HSP70-peptide complexes promote the proliferation of hepatocellular carcinoma cells via TLR2/4/JNK1/2MAPK pathway.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Interindividual variation in gene expression responses and metabolite formation in acetaminophen-exposed primary human hepatocytes.Archives of toxicology · 2016Article
- Innate immunity and hepatocarcinoma: Can toll-like receptors open the door to oncogenesis?World journal of hepatology · 2016Review
- Toll-like receptor 2 and type 2 diabetes.Cellular & molecular biology letters · 2016Review
- Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.World journal of gastroenterology · 2015Review
- Emerging role of Toll-like receptor 4 in hepatocellular carcinoma.Journal of hepatocellular carcinoma · 2015Review
- LPS promotes epithelial-mesenchymal transition and activation of TLR4/JNK signaling.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-κB signaling pathway.Oncotarget · 2014Article
- Role of innate immunity in the development of hepatocellular carcinoma.World journal of gastroenterology · 2013Review
- Perihepatic lymph node enlargement is a negative predictor of liver cancer development in chronic hepatitis C patients.Journal of gastroenterology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the third largest cause of cancer deaths worldwide. The role of molecular changes in HCC have been used to identify prognostic markers and chemopreventive or therapeutic targets. It seems that toll-like receptors (TLRs) as well as the nuclear factor (NF)-κB, and JNK pathways are critical regulators for the production of the cytokines associated with tumor promotion. The cross-talk between an inflammatory cell and a neoplastic cell, which is instigated by the activation of NF-κB and JNKs, is critical for tumor organization. JNKs also regulate cell proliferation and act as oncogenes, making them the main tumor-promoting protein kinases. TLRs play roles in cytokine and hepatomitogen expression mainly in myeloid cells and may promote liver tumorigenesis. A better understanding of these signaling pathways in the liver will help us understand the mechanism of hepatocarcinogenesis and provide a new therapeutic target for HCC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.